Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models

Abstract excerpt

-deleted VACVs, with application as a promising therapy for patients with BCG-refractory cancers and immune dysregulation.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytomegalovirus and herpesvirus research
• Share to Herpesvirus Infections and Treatments
• Share to Virus-based gene therapy research